Codexis Inc (CDXS) - Financial and Strategic SWOT Analysis Review

May 2021 | 53 pages | ID: CE6DE244E310EN
GlobalData

Abstracts

Codexis Inc (CDXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Codexis Inc (Codexis) is a protein engineering company, which discovers, develops and markets proteins for a wide range of applications. It sells biocatalysts for the commercial manufacture of pharmaceuticals, industrial enzymes and fine chemicals, and enzymes as biotherapeutics and for use in molecular diagnostics. The company identifies, optimizes and produces enzymes by using CodeEvolver, its proprietary protein engineering technology platform, which introduces mutation into genes to transform the enzymes that they produce. It also offers a range of biocatalysis solutions including robotic high-throughput screening, organic chemistry and process development, and genomic sequencing. The company serves pharmaceutical, food manufacturing and chemical companies. Codexis is headquartered in Redwood City, California, the US.

Codexis Inc Key Recent Developments

Apr 22,2021: Codexis to Report First Quarter 2021 Financial Results on May 6
Feb 25,2021: Codexis reports fourth quarter and fiscal year 2020 financial results
Feb 09,2021: Codexis announces expansion to new facility to accommodate next stage of growth
Feb 03,2021: Codexis appoints Dr. Esther Martinborough to its Board of Directors
Aug 06,2020: Codexis adds Dr. Jennifer L. Aaker to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Codexis Inc - Key Facts
Codexis Inc - Key Employees
Codexis Inc - Key Employee Biographies
Codexis Inc - Major Products and Services
Codexis Inc - History
Codexis Inc - Company Statement
Codexis Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Codexis Inc - Business Description
Business Segment: Novel Biotherapeutics
Overview
Performance
Business Segment: Performance Enzymes
Overview
Performance
Geographical Segment: Americas
Performance
Geographical Segment: APAC
Performance
Geographical Segment: EMEA
Performance
R&D Overview
Codexis Inc - Corporate Strategy
Codexis Inc - SWOT Analysis
SWOT Analysis - Overview
Codexis Inc - Strengths
Codexis Inc - Weaknesses
Codexis Inc - Opportunities
Codexis Inc - Threats
Codexis Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Codexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Codexis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Codexis Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 22, 2021: Codexis to Report First Quarter 2021 Financial Results on May
Feb 25, 2021: Codexis reports fourth quarter and fiscal year 2020 financial results
Feb 09, 2021: Codexis announces expansion to new facility to accommodate next stage of growth
Feb 03, 2021: Codexis appoints Dr. Esther Martinborough to its Board of Directors
Aug 06, 2020: Codexis adds Dr. Jennifer L. Aaker to its Board of Directors
Aug 06, 2020: Codexis reports second quarter 2020 financial results
Jun 16, 2020: Codexis announces the election of new directors at its annual meeting of stockholders
May 07, 2020: Codexis reports first quarter 2020 financial results
May 06, 2020: Codexis achieves technology transfer milestone with global pharmaceutical leader
May 05, 2020: Codexis expands and strengthens its leadership team with two executive hires

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Codexis Inc, Key Facts
Codexis Inc, Key Employees
Codexis Inc, Key Employee Biographies
Codexis Inc, Major Products and Services
Codexis Inc, History
Codexis Inc, Subsidiaries
Codexis Inc, Key Competitors
Codexis Inc, Ratios based on current share price
Codexis Inc, Annual Ratios
Codexis Inc, Annual Ratios (Cont...1)
Codexis Inc, Interim Ratios
Codexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Codexis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Codexis Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Codexis Inc, Performance Chart (2016 - 2020)
Codexis Inc, Ratio Charts
Codexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Codexis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021